- Home
- GRAB vs GMAB Comparison
GRAB vs GMAB Comparison
Compare GRAB & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAB
- GMAB
- Stock Information
- Founded
- GRAB 2012
- GMAB 1999
- Country
- GRAB Singapore
- GMAB Denmark
- Employees
- GRAB N/A
- GMAB N/A
- Industry
- GRAB Business Services
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GRAB Consumer Discretionary
- GMAB Health Care
- Exchange
- GRAB Nasdaq
- GMAB Nasdaq
- Market Cap
- GRAB 17.4B
- GMAB 15.0B
- IPO Year
- GRAB N/A
- GMAB N/A
- Fundamental
- Price
- GRAB $5.07
- GMAB $20.65
- Analyst Decision
- GRAB Buy
- GMAB Buy
- Analyst Count
- GRAB 9
- GMAB 8
- Target Price
- GRAB $5.61
- GMAB $43.00
- AVG Volume (30 Days)
- GRAB 47.2M
- GMAB 1.5M
- Earning Date
- GRAB 11-11-2024
- GMAB 11-06-2024
- Dividend Yield
- GRAB N/A
- GMAB N/A
- EPS Growth
- GRAB N/A
- GMAB 14.35
- EPS
- GRAB N/A
- GMAB 10.80
- Revenue
- GRAB $2,686,000,000.00
- GMAB $2,967,926,227.00
- Revenue This Year
- GRAB $18.74
- GMAB $30.31
- Revenue Next Year
- GRAB $16.92
- GMAB $16.49
- P/E Ratio
- GRAB N/A
- GMAB $18.68
- Revenue Growth
- GRAB 21.65
- GMAB 17.75
- 52 Week Low
- GRAB $2.90
- GMAB $20.34
- 52 Week High
- GRAB $5.72
- GMAB $32.88
- Technical
- Relative Strength Index (RSI)
- GRAB 62.54
- GMAB 29.22
- Support Level
- GRAB $4.59
- GMAB $20.34
- Resistance Level
- GRAB $5.72
- GMAB $23.47
- Average True Range (ATR)
- GRAB 0.26
- GMAB 0.46
- MACD
- GRAB 0.08
- GMAB -0.12
- Stochastic Oscillator
- GRAB 61.08
- GMAB 9.90
About GRAB Grab Holdings Limited
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore and Malaysia contributed 58% of revenue as of end-2021. Grab's main competitors in Southeast Asia are Foodpanda and Gojek, the ride-sharing arm of GoTo. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.